First, there was a preclinical study in melanoma demonstrating that the combination of CDK4/6 plus MEK inhibitors has greater efficacy in immunocompetent models relative to immunodeficient models, and that CD8 + T cells contribute to the antitumor effects of this combination [34]. The gene discussed is MAP2K7; the disease is melanoma.